Genetic ablation of CD68 results in mice with increased bone and dysfunctional osteoclasts

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Ashley, Jason W ^a   Shi, Zhenqi ^a   Zhao, Haibo ^b   Li, Xingsheng ^c   Kesterson, Robert A ^d   Feng, Xu ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; COLONY STIMULATING FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; CD68 PROTEIN, MOUSE; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN PRESENTATION; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; MACROPHAGE; MOLECULAR WEIGHT; MONOCYTE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; PHAGOCYTOSIS; WESTERN BLOTTING; ANIMAL; BONE; BONE DENSITY; BONE DEVELOPMENT; BONE MARROW CELL; CATTLE; CELL CULTURE; GENE DELETION; GENETICS; METABOLISM; OSTEOBLAST; OSTEOLYSIS; PATHOLOGY; PHENOTYPE; PROTEIN TRANSPORT;

MUS;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BONE AND BONES; BONE DENSITY; BONE MARROW CELLS; BONE RESORPTION; CATTLE; CELLS, CULTURED; GENE DELETION; MACROPHAGES; MICE; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; PHENOTYPE; PROTEIN TRANSPORT;

EID: 80053454233     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025838     Document Type: Article

References (42)

1. Graeber MB, Streit WJ, Kiefer R, Schoen SW, Kreutzberg GW, (1990) New expression of myelomonocytic antigens by microglia and perivascular cells following lethal motor neuron injury. J Neuroimmunol 27: 121-132.
2. Tomita M, Yamamoto K, Kobashi H, Ohmoto M, Tsuji T, (1994) Immunohistochemical phenotyping of liver macrophages in normal and diseased human liver. Hepatology 20: 317-325.
3. Athanasou NA, Puddle B, Quinn J, Woods CG, (1991) Use of monoclonal antibodies to recognise osteoclasts in routinely processed bone biopsy specimens. J Clin Pathol 44: 664-666.
4. Taylor R, Knowles HJ, Athanasou NA, (2011) Ewing sarcoma cells express RANKL and support osteoclastogenesis. J Pathol 225: 195-202.
5. Bruun JM, Helge JW, Richelsen B, Stallknecht B, (2006) Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am J Physiol Endocrinol Metab 290: E961-967.
6. Liu C, Tao Q, Sun M, Wu JZ, Yang W, et al. (2010) Kupffer cells are associated with apoptosis, inflammation and fibrotic effects in hepatic fibrosis in rats. Lab Invest 90: 1805-1816.
7. Mäkitie T, Summanen P, Tarkkanen A, Kivelä T, (2001) Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 42: 1414-1421.
8. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA, (2008) Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 15: 1069-1074.
9. Li AC, Guidez FR, Collier JG, Glass CK, (1998) The macrosialin promoter directs high levels of transcriptional activity in macrophages dependent on combinatorial interactions between PU.1 and c-Jun. J Biol Chem 273: 5389-5399.
10. Gough PJ, Gordon S, Greaves DR, (2001) The use of human CD68 transcriptional regulatory sequences to direct high-level expression of class A scavenger receptor in macrophages in vitro and in vivo. Immunology 103: 351-361.
11. Gough PJ, Raines EW, (2003) Gene therapy of apolipoprotein E-deficient mice using a novel macrophage-specific retroviral vector. Blood 101: 485-491.
12. Ramprasad MP, Fischer W, Witztum JL, Sambrano GR, Quehenberger O, et al. (1995) The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Proc Natl Acad Sci U S A 92: 9580-9584.
13. Ramprasad MP, Terpstra V, Kondratenko N, Quehenberger O, Steinberg D, (1996) Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. Proc Natl Acad Sci U S A 93: 14833-14838.
14. Kurushima H, Ramprasad M, Kondratenko N, Foster DM, Quehenberger O, et al. (2000) Surface expression and rapid internalization of macrosialin (mouse CD68) on elicited mouse peritoneal macrophages. J Leukoc Biol 67: 104-108.
15. van der Kooij MA, von der Mark EM, Kruijt JK, van Velzen A, van Berkel TJ, et al. (1997) Human monocyte-derived macrophages express an approximately 120-kD Ox-LDL binding protein with strong identity to CD68. Arterioscler Thromb Vasc Biol 17: 3107-3116.
16. Zeibig S, Li Z, Wagner S, Holthoff HP, Ungerer M, et al. (2011) Effect of the oxLDL binding protein Fc-CD68 on plaque extension and vulnerability in atherosclerosis. Circ Res 108: 695-703.
17. Van Velzen AG, Da Silva RP, Gordon S, Van Berkel TJ, (1997) Characterization of a receptor for oxidized low-density lipoproteins on rat Kupffer cells: similarity to macrosialin. Biochem J 322 (Pt 2): 411-415.
18. de Beer MC, Zhao Z, Webb NR, van der Westhuyzen DR, de Villiers WJ, (2003) Lack of a direct role for macrosialin in oxidized LDL metabolism. J Lipid Res 44: 674-685.
19. Llaverias G, Noé V, Peñuelas S, Vázquez-Carrera M, Sánchez RM, et al. (2004) Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages. Biochem Biophys Res Commun 318: 265-274.
20. Li S, Lee C, Schindler C, (2011) Deletion of the murine scavenger receptor CD68. J Lipid Res 52: 1542-1550.
21. Rabinowitz SS, Gordon S, (1991) Macrosialin, a macrophage-restricted membrane sialoprotein differentially glycosylated in response to inflammatory stimuli. J Exp Med 174: 827-836.
22. da Silva RP, Gordon S, (1999) Phagocytosis stimulates alternative glycosylation of macrosialin (mouse CD68), a macrophage-specific endosomal protein. Biochem J 338 (Pt 3): 687-694.
23. Burghardt AJ, Kazakia GJ, Laib A, Majumdar S, (2008) Quantitative assessment of bone tissue mineralization with polychromatic micro-computed tomography. Calcif Tissue Int 83: 129-138.
24. Hall SL, Lau KH, Chen ST, Wergedal JE, Srivastava A, et al. (2007) Sca-1(+) hematopoietic cell-based gene therapy with a modified FGF-2 increased endosteal/trabecular bone formation in mice. Mol Ther 15: 1881-1889.
25. Karsdal MA, Martin TJ, Bollerslev J, Christiansen C, Henriksen K, (2007) Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res 22: 487-494.
26. Karsdal MA, Neutzsky-Wulff AV, Dziegiel MH, Christiansen C, Henriksen K, (2008) Osteoclasts secrete non-bone derived signals that induce bone formation. Biochem Biophys Res Commun 366: 483-488.
27. Coxon FP, Taylor A, (2008) Vesicular trafficking in osteoclasts. Semin Cell Dev Biol 19: 424-433.
28. Zhao H, Laitala-Leinonen T, Parikka V, Väänänen HK, (2001) Downregulation of small GTPase Rab7 impairs osteoclast polarization and bone resorption. J Biol Chem 276: 39295-39302.
29. Van Wesenbeeck L, Odgren PR, Coxon FP, Frattini A, Moens P, et al. (2007) Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J Clin Invest 117: 919-930.
30. Pavlos NJ, Xu J, Riedel D, Yeoh JS, Teitelbaum SL, et al. (2005) Rab3D regulates a novel vesicular trafficking pathway that is required for osteoclastic bone resorption. Mol Cell Biol 25: 5253-5269.
31. Pavlos NJ, Cheng TS, Qin A, Ng PY, Feng HT, et al. (2011) Tctex-1, a novel interaction partner of Rab3D, is required for osteoclastic bone resorption. Mol Cell Biol 31: 1551-1564.
32. Luegmayr E, Glantschnig H, Wesolowski GA, Gentile MA, Fisher JE, et al. (2004) Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins. Cell Death Differ 11 (Suppl 1): S108-118.
33. Zhao H, Väänänen HK, (2006) Pharmacological sequestration of intracellular cholesterol in late endosomes disrupts ruffled border formation in osteoclasts. J Bone Miner Res 21: 456-465.
34. Coxon FP, Helfrich MH, Larijani B, Muzylak M, Dunford JE, et al. (2001) Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem 276: 48213-48222.
35. Alakangas A, Selander K, Mulari M, Halleen J, Lehenkari P, et al. (2002) Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int 70: 40-47.
36. Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FP, (2010) Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 16: 2950-2960.
37. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, et al. (2000) Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 105: 433-440.
38. Takeshita S, Kaji K, Kudo A, (2000) Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res 15: 1477-1488.
39. Xu D, Wang S, Liu W, Liu J, Feng X, (2006) A novel receptor activator of NF-kappaB (RANK) cytoplasmic motif plays an essential role in osteoclastogenesis by committing macrophages to the osteoclast lineage. J Biol Chem 281: 4678-4690.
40. Jules J, Shi Z, Liu J, Xu D, Wang S, et al. (2010) Receptor activator of NF-{kappa}B (RANK) cytoplasmic IVVY535-538 motif plays an essential role in tumor necrosis factor-{alpha} (TNF)-mediated osteoclastogenesis. J Biol Chem 285: 37427-37435.
41. Minkin C, (1982) Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 34: 285-290.
42. Carron CP, Meyer DM, Engleman VW, Rico JG, Ruminski PG, et al. (2000) Peptidomimetic antagonists of alphavbeta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone. J Endocrinol 165: 587-598.